View PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.

PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.

This programme, (supported by CEPI funding), will provide the infrastructure to help design and select the lead antigen through proof-of-concept preclinical studies, progressing to initial clinical development through Phase I/II studies. DIOSynVax aim to establish clinical proof of concept for a novel vaccine candidate with the potential to provide broad protection against Sarbecovirus, Merbecovirus, Embecovirus and Nobecovirus.

Read More

View Adopting a New Agile Approach to CRO Clinical Trial Management

Adopting a New Agile Approach to CRO Clinical Trial Management

Following its reputation of excellence in delivering investigator-led studies, PHARMExcel was selected to manage the Covid-19 vaccine booster study.

Read More

View Employee Spotlight: Krishna Askoolam

Employee Spotlight: Krishna Askoolam

Meet Krishna Askoolam, Clinical Trials Administrator: “This is my first role fresh out of University having graduated with a First-Class Honours degree in Biochemistry from the University of Kent…”

Read More

View New EU Clinical Trial Regulation

New EU Clinical Trial Regulation

The new EU clinical trial regulation (CTR) is set to revolutionise clinical trial processes across Europe impacting all European Member states and organisations wanting to run clinical trials across these regions. How can organisations prepare for the change and set themselves up successfully with a new CTR programme?

Read More

View Employee Spotlight: Martha Nabunjo

Employee Spotlight: Martha Nabunjo

Meet Martha Nabunjo Clinical Research Associate I (Clinical Monitor) “I’ve worked at PHARMExcel almost a year now and I must say in this short space of time, I am very lucky to have had the opportunity to work on some very high-profile studies. What I enjoy most about my role here is that every day…

Read More

View Yvanne Enever, Founder/CEO reflects on 2021

Yvanne Enever, Founder/CEO reflects on 2021

We are pleased to say that 2021 has seen PHARMExcel busier than ever. From delivering the Worlds’ first Booster Vaccine clinical trial leading to the shaping of UK Government policy, to welcoming new, key staff appointments and undertaking several charity events for Macmillan Cancer Support, Team PHARMExcel showed dedication to the cause. As we complete…

Read More

View PHARMExcel delighted to be the selected U.K. CRO delivering this pivotal clinical trial alongside colleagues at University Southampton, Cambridge and DIOSynVax.

PHARMExcel delighted to be the selected U.K. CRO delivering this pivotal clinical trial alongside colleagues at University Southampton, Cambridge and DIOSynVax.

Read More

View PHARMExcel are pleased to announce the publication of the safety and immunogenicity data from the UK’s Covboost trial.

PHARMExcel are pleased to announce the publication of the safety and immunogenicity data from the UK’s Covboost trial.

Read More

View October marks Day 1 for our 100k run challenge

October marks Day 1 for our 100k run challenge

The 1st October marks Day 1 for our 100k run challenge. Yvanne Enever will be running 100k during the month of Oct to raise money for PHARMExcel’s chosen charity, Macmillan Cancer Support. Yvanne said..”as a former runner (semi retired due to injury!) this is exciting and daunting at the same time, but I am determined…

Read More